OTHER ASIA
Other Asia comprises all Asian territories excluding China. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia. Therapies that dominate in these regions include Anaesthetics and certain Regional Brands. Our manufacturing facility in India is our primary new product development site.
Key Countries and Territories
Hong Kong
Philippines
Singapore
Taiwan

- The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024.
- The Indonesian pharmaceutical market is forecast to grow at a CAGR of 2% between 2019 and 2024, reaching Rp87,578 billion by 2024.
Source: IQVIA Market Prognosis 2020-2024
STATISTICS
Number of products launched:
1
(2019: 2)
Average staff turnover:
19%
(2019: 24%)
Number of product recalls:
Nil
(2019: Nil)
Number of work-related fatalities:
Nil
(2019: Nil)
Number of permanent employees | ||
525June 2020 |
482June 2019 |
Revenue | 2020 R’million |
2019 (CER) R’million |
Change % |
||||
---|---|---|---|---|---|---|---|
Regional Brands | 546 | 559 | (2) | ||||
Sterile Focus Brands | 835 | 934 | (11) | ||||
Anaesthetics Brands | 691 | 749 | (8) | ||||
Thrombosis Brands | 144 | 185 | (22) | ||||
Total Commercial Pharmaceuticals | 1 381 | 1 493 | (8) | ||||
Manufacturing – API | 115 | 121 | 2 | ||||
Total | 1 496 | 1 614 | (7) |
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.